This website is not optimized for your browser version. Update to the latest Internet Explorer Version for a safer and faster web experience
2019 Australian Pain Society 39th Annual Scientific Meeting

2019 Australian Pain Society 39th Annual Scientific MeetingIn the IASP Global Year Against Pain in the Most Vulnerable7 - 10 April 2019 | Gold Coast Convention and Exhibition Centre, QLD

Sponsored Sessions

Monday 8 April 2019 - 7.15 - 8.15am (includes breakfast) - Registration required

'Is there a role for opioids in patients with chronic non-cancer pain?

Presenter: Professor Milton Cohen

The role of opioids in the management of patients with chronic non-cancer pain is the subject of hotly contested controversy that essentially pitches evidence against empiricism. This session is not intended to resolve this controversy but rather to provide a map and compass to help the clinician navigate these difficult waters more effectively. Discussion will revolve around the following themes:

  • there are two “epidemics” occurring in parallel: one is inappropriate use of opioids (and indeed of other drugs), the other is chronic non-cancer pain itself
  • the phenotype of "chronic pain” is complex and needs to be assessed in a sociopsychobiomedical framework
  • drug therapy for patients with chronic non-cancer pain is only part of a multifaceted if not also multidisciplinary treatment approach
  • any pharmacotherapy, including opioids, for patients with chronic non-cancer pain is always an ongoing trial of therapy
  • in order to be effective pharmacotherapists for patients with chronic non-cancer pain, prescribers must have detailed knowledge of the pharmacology of all drugs used and of the regulations concerning their use

Tuesday 9 April 2019, 7.15 – 8.15 am (includes breakfast)

iX Biopharma 

Sublingual Ketamine Wafer: Phase 2b Results of Wafermine in Acute Post-Operative Pain

Presenters: Janakan Krishnarajah and Stephan Schug

Dr Krishnarajah, Chief Medical Officer of iX Biopharma Ltd, will present clinical trial results from the recently completed US Phase 2b study of Wafermine (sublingual ketamine wafer) in acute, moderate to severe post-operative pain.

Prof Stephan Schug, Chair of Anaesthesiology and Pain Medicine (UWA) and Director of Pain Medicine (Royal Perth Hospital), will provide an update on the latest research on the use of Ketamine for pain management.